Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

被引：0

作者：

A. Luna

L. Pérez-Lamas

C. Boque

P. Giraldo

B. Xicoy

C. Ruiz Nuño

M. Moreno Vega

A. Alvarez-Larrán

A. Salamanca

A. García-Noblejas

F. Vall-Llovera

L. Villalon

N. De las Heras

E. Ramila

M. Pérez-Encinas

B. Cuevas

R. Perez-Lopez

F. Sanchez-Guijo

A. Jiménez-Velasco

S. Lakhwani

L. Felipe Casado

A. Rosell

A. Escola

M. J. Fernández

C. Garcia-Hernandez

C. Cervero

E. Mora

M. Sagüés

S. Suarez-Varela

P. Vélez

P. Carrascosa Mastell

R. F. Bitaube

L. Serrano

M. Cortes

J.A Vera Goñi

J. L. Steegmann

V. Gomez Garcia de Soria

J. M. Alonso-Dominguez

M. Colorado Araujo

A. Paz Coll

J.C Hernandez-Boluda

V. García-Gutiérrez

机构：

[1] Hospital Universitario Ramón y Cajal,Hematology Department

[2] IRYCIS,Institut Catala d’Oncologia

[3] Universidad de Alcala,Department of Medicine, University of Salamanca, Hematology Department

[4] Hospital Duran Y Reynals,undefined

[5] L’Hospitalet de Llobregat,undefined

[6] Hospital Quirón Zaragoza,undefined

[7] Institut Català d’Oncologia-Hospital Germans Trias I Pujol,undefined

[8] Hospital Regional Universitario de Málaga,undefined

[9] Hospital Doctor José Molina Orosa de Lanzarote,undefined

[10] Hospital Clinic de Barcelona,undefined

[11] Hospital de Jerez de La Frontera,undefined

[12] Hospital Universitario de La Princesa,undefined

[13] Hospital Mutua de Terrassa,undefined

[14] Hospital Universitario Fundación Alcorcón,undefined

[15] Hospital Universitario de León,undefined

[16] Hospital Parc Tauli,undefined

[17] Hospital Clínico Universitario de Santiago de Compostela,undefined

[18] Hospital Universitario de Burgos,undefined

[19] Hospital Universitario Clínico Virgen de La Arrixaca,undefined

[20] IBSAL-University Hospital of Salamanca,undefined

[21] Hospital Universitario Carlos Haya,undefined

[22] Hospital Universitario de Canarias,undefined

[23] Hospital Virgen de La Salud,undefined

[24] Hospital Virgen de La Victoria,undefined

[25] Hospital Provincial de Castellón,undefined

[26] Hospital Doctor Peset,undefined

[27] Hospital General de Alicante,undefined

[28] Hospital Virgen de La Luz,undefined

[29] Hospital Universitario Y Politécnico La Fe,undefined

[30] Hospital General de Castellón,undefined

[31] Hospital de Granollers,undefined

[32] Hospital Virgen Macarena,undefined

[33] Hospital Universitario Fundación Jiménez Díaz,undefined

[34] Hospital Universitario Marqués de Valdecilla,undefined

[35] Hospital Universitario Puerto Real,undefined

[36] Hospital Clínico Universitario-INCLIVA,undefined

[37] University of Valencia,undefined

来源：

Annals of Hematology | 2022年 / 101卷

关键词：

Leukemia; Inhibitors; Asciminib ;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated in clinical trials a good efficacy and safety profile after failure of 2GTKI. However, no study has specifically addressed response rates to asciminib in ponatinib pretreated patients (PPT). Here, we present data on responses to asciminib from 52 patients in clinical practice, 20 of them (38%) with prior ponatinib exposure. We analyzed retrospectively responses and toxicities under asciminib and compared results between PPT and non-PPT patients.

引用

页码：2263 / 2270

页数：7

共 50 条

[1] Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Luna, A.
Perez-Lamas, L.
Boque, C.
Giraldo, P.
Xicoy, B.
Ruiz Nuno, C.
Moreno Vega, M.
Alvarez-Larran, A.
Salamanca, A.
Garcia-Noblejas, A.
Vall-Llovera, F.
Villalon, L.
De Las Heras, N.
Ramila, E.
Perez-Encinas, M.
Cuevas, B.
Perez-Lopez, R.
Sanchez-Guijo, F.
Jimenez-Velasco, A.
Lakhwani, S.
Felipe Casado, L.
Rosell, A.
Escola, A.
Fernandez, M. J.
Garcia-Hernandez, C.
Cervero, C.
Mora, E.
Sagues, M.
Suarez-Varela, S.
Velez, P.
Carrascosa Mastell, P.
Bitaube, R. F.
Serrano, L.
Cortes, M.
Vera Goni, J. A.
Steegmann, J. L.
Garcia de Soria, V. Gomez
Alonso-Dominguez, J. M.
Colorado Araujo, M.
Paz Coll, A.
Hernandez-Boluda, J. C.
Garcia-Gutierrez, V
ANNALS OF HEMATOLOGY, 2022, 101 (10) : 2263 - 2270
[2] Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients
Perez-Lamas, Lucia
Luna, Alejandro
Boque, Concepcion
Giraldo, Pilar
Xicoy, Blanca
Felipe Casado, Luis
Sanchez-Guijo, Fermin
Ruiz Nuno, Concepcion
Moreno Vega, Melania
Alvarez-Larran, Alberto
Salamanca Cuenca, Araceli
Garcia-Noblejas, Ana
Vall-Llovera, Ferran
Perez Encinas, Manuel
Villalon, Lucia
De las Heras, Natalia
Lakhwani, Sunil
Ramila, Elena
Cuevas, Beatriz
Perez Lopez, Raul
Jimenez-Velasco, Antonio
Rosell, Ana
Escola, Angeles
Jose Fernandez, Maria
Garcia-Hernandez, Carmen
Cervero, Carlos
Mora Castera, Elvira
Saguees, Miguel
Suarez-Varela, Sara
Velez, Patricia
Carrascosa Mastell, Patricia
Fe Bitaube, Rocio
Serrano, Luis
Cortes, Montse
Vera Goni, Juan Antonio Juan
Luis Steegmann, Juan
Hernandez Boluda, Juan Carlos
Gomez, Valle
Manuel Alonso-Dominguez, Juan
Colorado Araujo, Mercedes
Paz Coll, Antonio
Garcia Gutierrez, Valentin
BLOOD, 2021, 138
[3] Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Valentín Garcia-Gutiérrez
Alejandro Luna
Juan M. Alonso-Dominguez
Natalia Estrada
Concepcion Boque
Blanca Xicoy
Pilar Giraldo
Anna Angona
Alberto Alvarez-Larrán
Fermin Sanchez-Guijo
María José Ramírez
Elvira Mora
Patricia Vélez
Ana Rosell
Mercedes Colorado Araujo
Beatriz Cuevas
Miguel Sagüés
Montserrat Cortes
Manuel Perez Encinas
Luis Felipe Casado Montero
Melania Moreno Vega
Luis Serrano
Valle Gomez
Carmen Garcia-Hernandez
Sunil Lakhwani
Antonio Paz Coll
Raquel de Paz
Sara Suarez-Varela
Andrés Fernandez-Ruiz
Raul Perez Lopez
Almudena Ortiz-Fernández
Antonio Jiménez-Velasco
Juan Luis Steegmann-Olmedillas
Juan Carlos Hernández-Boluda
Blood Cancer Journal, 11
[4] Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Garcia-Gutierrez, Valentin
Luna, Alejandro
Alonso-Dominguez, Juan M.
Estrada, Natalia
Boque, Concepcion
Xicoy, Blanca
Giraldo, Pilar
Angona, Anna
Alvarez-Larran, Alberto
Sanchez-Guijo, Fermin
Ramirez, Maria Jose
Mora, Elvira
Velez, Patricia
Rosell, Ana
Colorado Araujo, Mercedes
Cuevas, Beatriz
Sagues, Miguel
Cortes, Montserrat
Encinas, Manuel Perez
Casado Montero, Luis Felipe
Moreno Vega, Melania
Serrano, Luis
Gomez, Valle
Garcia-Hernandez, Carmen
Lakhwani, Sunil
Paz Coll, Antonio
de Paz, Raquel
Suarez-Varela, Sara
Fernandez-Ruiz, Andres
Perez Lopez, Raul
Ortiz-Fernandez, Almudena
Jimenez-Velasco, Antonio
Steegmann-Olmedillas, Juan Luis
Hernandez-Boluda, Juan Carlos
BLOOD CANCER JOURNAL, 2021, 11 (02)
[5] Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia
Ishii, Yoshimi
Fujisawa, Shin
Miyazaki, Takuya
Nakajima, Yuki
Matsumura, Ayako
Fujimaki, Katsumichi
Suzuki, Taisei
Hagihara, Maki
Tanaka, Marika
Hashimoto, Chizuko
Nakajima, Hideaki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 187 - 193
[6] RESPONSES TO ASCIMINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PRIOR TREATMENT WITH PONATINIB
Alejandro, Luna
Juan, Alonso-Dominguez
Natalia, Estrada
Concepcion, Boque
Blanca, Xicoy
Pilar, Giraldo
Anna, Angona
Alberto, Alvarez-Larran
Fermin, Sanchez-Guijo
Maria Jose, Ramirez
Elvira, Mora
Patricia, Velez
Ana, Rossell
Araujo Mercedes, Colorado
Beatriz, Cuevas
Montserrat, Cortes
Encinas Manuel, Perez
Luis Felipe, Casado Montero
Vega Melania, Moreno
Valle, Gomez
Sunil, Lakhwani
Lamas Lucia, Perez
Juan Luis, Steegmann Olmedillas
Juan Carlos, Hernandez Boluda
Valentin, Garcia-Gutierrez
HAEMATOLOGICA, 2021, 106 (10) : 21 - 21
[7] Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study
Shacham-Abulafia, Adi
Raanani, Pia
Lavie, David
Volchek, Yulia
Ram, Ron
Helman, Ilana
Shargian, Liat
Gourevitch, Anna
Chubar, Evgeni
Ratzon, Roy
Rozovski, Uri
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (07): : E295 - E301
[8] ASCIMINIB WITH PONATINIB LOWERS RESISTANCE IN CHRONIC MYELOID LEUKEMIA
不详
CANCER DISCOVERY, 2019, 9 (11) : 1481 - 1481
[9] Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
Breccia, Massimo
Abruzzese, Elisabetta
Castagnetti, Fausto
Bonifacio, Massimiliano
Gangemi, Domenica
Sora, Federica
Iurlo, Alessandra
Luciano, Luigiana
Gozzini, Antonella
Gentile, Massimo
Bocchia, Monica
Luzi, Debora
Maggi, Alessandro
Sgherza, Nicola
Isidori, Alessandro
Crugnola, Monica
Pregno, Patrizia
Scortechini, Anna Rita
Capodanno, Isabella
Pizzuti, Michele
Foa, Robin
ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1577 - 1580
[10] Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
Massimo Breccia
Elisabetta Abruzzese
Fausto Castagnetti
Massimiliano Bonifacio
Domenica Gangemi
Federica Sorà
Alessandra Iurlo
Luigiana Luciano
Antonella Gozzini
Massimo Gentile
Monica Bocchia
Debora Luzi
Alessandro Maggi
Nicola Sgherza
Alessandro Isidori
Monica Crugnola
Patrizia Pregno
Anna Rita Scortechini
Isabella Capodanno
Michele Pizzuti
Robin Foà
Annals of Hematology, 2018, 97 : 1577 - 1580

← 1 2 3 4 5 →